iShares Nasdaq US Biotechnology UCITS ETF USD (Acc) (BTEK)
Category Sector Equity Biotechnology
This ETF can be held in an Investment ISA, SIPP and Investment Account
Sell
£4.985
Buy
£4.998
£0.018 (+0.36%)
Prices updated at 14 Mar 2025, 16:35 GMT
| Prices minimum 15 mins delay
|
Prices in GBP
Investment objective
The investment objective of the Fund is to seek to provide investors with a total return, taking into account both capital and income returns, which reflects the return of the NASDAQ Biotechnology Index.
Important notice: This product is based overseas and is not subject to UK sustainable investment labelling and disclosure requirements. Please refer to the FCA website which details further information in relation to sustainability disclosure requirements for retail clients.
Important documents: Please ensure that you have read the Key Information Document/Technical Guide
, Pre-sale Illustrations document & Doing Business with Fidelity document (incorporating the Fidelity Client Terms) and the fund information documents. These can be found within the Charges & documents section.
- Key stats
- Price
- Performance
- Charges & documents
- Dividends
- Portfolio
- Risk profile
- Management
Portfolio as of 12/03/2025
Asset allocation
Show long & short position
Geographical breakdown
Continent or country allocation (%)
Market classification (%)
Stock style
Large value
37.21%
% Weight
Value
Core
Growth
Large
37
2
6
Medium
8
6
9
Small
6
11
15
Valuation
iShares Nasdaq US Biotechnology UCITS ETF USD (Acc)
Sector Equity Biotechnology
14.92
3.95
3.49
13.02
Growth rate
iShares Nasdaq US Biotechnology UCITS ETF USD (Acc)
Sector Equity Biotechnology
16.10%
0.86%
-13.67%
Top 10 holdings
Security name | Sector | Country | % of assets | |
---|---|---|---|---|
1 | Gilead Sciences Inc | - | United States | 10.31 |
2 | Amgen Inc | - | United States | 9.25 |
3 | Vertex Pharmaceuticals Inc | - | United States | 8.86 |
4 | Regeneron Pharmaceuticals Inc | - | United States | 7.21 |
5 | AstraZeneca PLC ADR | - | United Kingdom | 4.26 |
6 | Alnylam Pharmaceuticals Inc | - | United States | 3.03 |
7 | Biogen Inc | - | United States | 1.98 |
8 | argenx SE ADR | - | United States | 1.85 |
9 | Sanofi SA ADR | - | France | 1.68 |
10 | Summit Therapeutics Inc Ordinary Shares | - | United States | 1.42 |
Assets in top 10 holdings %
49.84%
Total no. of equity holdings
264.00
Total no. of bond holdings
-
Stock sectors
iShares Nasdaq US Biotechnology UCITS ETF USD (Acc)
Sector Equity Biotechnology
0.00%
Basic materials
Con cyclical
Financial svs
Real estate
0.00%
Comm services
Energy
Industrials
Technology
100.00%
Con defensive
Healthcare
Utilities